Sign inJoin waitlistJoin the waitlist

Yanyan Lou

Professor of Oncology · Mayo Clinic College of Medicine and Science

Credentials: · · · · ·

History

Mayo Clinic College of Medicine and Science
Present

Hematology/Oncology University of Texas MD Anderson Cancer Center
2000–2003
Melanoma Medical Oncology University of Texas MD Anderson Cancer Center
National Institutes of Health
Univ of Texas Southwestern Med Sch at Dallas
1997–2000
Henan Medical University
1993–1997

Research

Next generation of immune checkpoint therapy in cancer: new developments and challenges
Review · Journal of Hematology & Oncology · 2018 · Last of 6 authors · Corresponding · 630 citations
Next generation of immune checkpoint inhibitors and beyond
Review · Journal of Hematology & Oncology · 2021 · Last of 3 authors · Corresponding · 454 citations
Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung…
Clinical Cancer Research · 2016 · First of 15 authors · 389 citations

Rami Manochakian
36 papers
Yujie Zhao
28 papers
Shenduo Li
19 papers · 1 as a fellow
Patrick Hwu
14 papers
Alex Adjei
11 papers
Aaron Mansfield
8 papers
John Heymach
7 papers
Julian Acevedo
7 papers · 6 as a fellow
Umair Majeed
7 papers
AS
Aixa Soyano
6 papers · 6 as a fellow
Bhagirathbhai Dholaria
6 papers · 5 as a fellow
Don Gibbons
6 papers

Clinical trials

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Principal investigator · Recruiting · Phase 1, Phase 2
Mayo Clinic
2022–2028
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
Principal investigator · Active not recruiting
OncoHost Ltd.
2019–2029
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
Principal investigator · Completed · Phase 1, Phase 2
Mayo Clinic
2014–2023
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Site PI · Recruiting · Phase 1, Phase 2
A2 Biotherapeutics Inc.
2025–2030